{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:19:13Z","timestamp":1795105153776,"version":"4.10.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0692, W81XWH1910285, HT94252410543"],"award-info":[{"award-number":["W81XWH-22-1-0692, W81XWH1910285, HT94252410543"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K01HL171464, R01HL146402"],"award-info":[{"award-number":["K01HL171464, R01HL146402"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1272732"],"award-info":[{"award-number":["24CDA1272732"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1272732"],"award-info":[{"award-number":["24CDA1272732"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003284","name":"Pulmonary Fibrosis Foundation","doi-asserted-by":"publisher","award":["1053163"],"award-info":[{"award-number":["1053163"]}],"id":[{"id":"10.13039\/100003284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003284","name":"Pulmonary Fibrosis Foundation","doi-asserted-by":"publisher","award":["1053163"],"award-info":[{"award-number":["1053163"]}],"id":[{"id":"10.13039\/100003284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA257837, R01CA206458, U54CA268069, P30CA014520"],"award-info":[{"award-number":["R01CA257837, R01CA206458, U54CA268069, P30CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008590","name":"Dr. Ralph and Marian Falk Medical Research Trust","doi-asserted-by":"publisher","award":["Falk Transformational Award"],"award-info":[{"award-number":["Falk Transformational Award"]}],"id":[{"id":"10.13039\/100008590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","award":["Trewartha Senior Thesis Research Award, Honors Summer Senior Thesis Research Grant Award"],"award-info":[{"award-number":["Trewartha Senior Thesis Research Award, Honors Summer Senior Thesis Research Grant Award"]}],"id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Progressive forms of interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), are deadly disorders lacking non-invasive biomarkers for assessment of early disease activity, which presents a major obstacle in disease management. Excessive extracellular matrix (ECM) deposition is a hallmark of these disorders, with fibronectin being an abundant ECM glycoprotein that is highly upregulated in early fibrosis and serves as a scaffold for the deposition of other matrix proteins. Due to its role in active fibrosis, we are targeting fibronectin as a biomarker of early lung fibrosis disease activity via the PEGylated fibronectin-binding polypeptide (PEG-FUD). In this work, we demonstrate the binding of PEG-FUD to the fibrotic lung throughout the course of bleomycin-induced murine model of pulmonary fibrosis. We first analyzed the binding of radiolabeled PEG-FUD following direct incubation to precision cut lung slices from mice at different stages of experimental lung fibrosis. Then, we administered fluorescently labeled PEG-FUD subcutaneously to mice over the course of bleomycin-induced pulmonary fibrosis and assessed peptide uptake 24\u00a0h later through ex vivo tissue imaging. Using both methods, we found that peptide targeting to the fibrotic lung is increased during the fibrogenic phase of the single dose bleomycin lung fibrosis model (days 7 and 14 post-bleomycin). At these timepoints we found a correlative relationship between peptide uptake and fibrotic burden. These data suggest that PEG-FUD targets fibronectin associated with active fibrogenesis in this model, making it a promising candidate for a clinically translatable molecular imaging probe to non-invasively determine pulmonary fibrosis disease activity, enabling accelerated therapeutic decision-making.<\/jats:p>","DOI":"10.1186\/s12931-025-03107-x","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T13:43:02Z","timestamp":1737553382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The fibronectin-targeting PEG-FUD imaging probe shows enhanced uptake during fibrogenesis in experimental lung fibrosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Thomas J.","family":"Harr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Rahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira","family":"Medina-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metti K.","family":"Gari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie T.","family":"Oler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy Sohee","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Rasoulianboroujeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Weichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Forati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Holbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor S.","family":"Langel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kade W.","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Burkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca R.","family":"Tomasini-Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Ponik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Sandbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Bernau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"3107_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/crj.13466","volume":"16","author":"DS Glass","year":"2022","unstructured":"Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, Reiss AB. Idiopathic pulmonary fibrosis: current and future treatment. Clin Respir J. 2022;16:84\u201396.","journal-title":"Clin Respir J"},{"key":"3107_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1378\/chest.111.1.51","volume":"111","author":"R Erbes","year":"1997","unstructured":"Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest. 1997;111:51\u20137.","journal-title":"Chest"},{"key":"3107_CR5","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR6","doi-asserted-by":"publisher","first-page":"e12871","DOI":"10.15252\/emmm.202012871","volume":"13","author":"CH Mayr","year":"2021","unstructured":"Mayr CH, Simon LM, Leuschner G, Ansari M, Schniering J, Geyer PE, Angelidis I, Strunz M, Singh P, Kneidinger N, et al. Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Mol Med. 2021;13:e12871.","journal-title":"EMBO Mol Med"},{"key":"3107_CR7","doi-asserted-by":"publisher","first-page":"16559","DOI":"10.1038\/s41598-023-43834-z","volume":"13","author":"Z Wu","year":"2023","unstructured":"Wu Z, Chen H, Ke S, Mo L, Qiu M, Zhu G, Zhu W, Liu L. Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis. Sci Rep. 2023;13:16559.","journal-title":"Sci Rep"},{"key":"3107_CR8","doi-asserted-by":"crossref","unstructured":"Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, Maher TM, Navaratnam V, Hubbard R, Hopkins PMA et al. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J 2022, 59.","DOI":"10.1183\/13993003.01181-2021"},{"key":"3107_CR9","doi-asserted-by":"crossref","unstructured":"Ji H, Song X, Lv X, Shao F, Long Y, Song Y, Song W, Qiao P, Gai Y, Jiang D, Lan X. [(68)Ga]FAPI PET for imaging and treatment monitoring in a preclinical model of pulmonary fibrosis: comparison to [(18)F]FDG PET and CT. Pharmaceuticals (Basel) 2024, 17.","DOI":"10.3390\/ph17060726"},{"key":"3107_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000088062","volume":"73","author":"HH Meissner","year":"2006","unstructured":"Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197\u2013202.","journal-title":"Respiration"},{"key":"3107_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","volume":"18","author":"A Justet","year":"2017","unstructured":"Justet A, Laurent-Bellue A, Thabut G, Dieudonne A, Debray MP, Borie R, Aubier M, Lebtahi R, Crestani B. [(18)F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18:74.","journal-title":"Respir Res"},{"key":"3107_CR12","doi-asserted-by":"crossref","unstructured":"Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR et al. [(68) Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging 2022.","DOI":"10.1007\/s00259-022-05814-9"},{"key":"3107_CR13","doi-asserted-by":"publisher","first-page":"eadm9817","DOI":"10.1126\/sciadv.adm9817","volume":"10","author":"PZ Mannes","year":"2024","unstructured":"Mannes PZ, Adams TS, Farsijani S, Barnes CE, Latoche JD, Day KE, Nedrow JR, Ahangari F, Kaminski N, Lee JS, Tavakoli S. Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1. Sci Adv. 2024;10:eadm9817.","journal-title":"Sci Adv"},{"key":"3107_CR14","doi-asserted-by":"crossref","unstructured":"Pommerolle L, Beltramo G, Biziorek L, Truchi M, Dias AMM, Dondaine L, Tanguy J, Pernet N, Goncalves V, Bouchard A et al. CD206(+) macrophages are relevant non-invasive imaging biomarkers and therapeutic targets in experimental lung fibrosis. Thorax 2024.","DOI":"10.1136\/thorax-2023-221168"},{"key":"3107_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1164\/rccm.202004-1132OC","volume":"203","author":"SL Brody","year":"2021","unstructured":"Brody SL, Gunsten SP, Luehmann HP, Sultan DH, Hoelscher M, Heo GS, Pan J, Koenitzer JR, Lee EC, Huang T, et al. Chemokine receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A clinical trial. Am J Respir Crit Care Med. 2021;203:78\u201389.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR16","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1038\/s41467-019-11863-w","volume":"10","author":"RH Kimura","year":"2019","unstructured":"Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, Guo HH, Haywood T, Abou-Elkacem L, Baratto L, et al. Evaluation of integrin alphavbeta6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nat Commun. 2019;10:4673.","journal-title":"Nat Commun"},{"key":"3107_CR17","doi-asserted-by":"crossref","unstructured":"Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P et al. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med 2017, 9.","DOI":"10.1126\/scitranslmed.aaf4696"},{"key":"3107_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1164\/rccm.201903-0503LE","volume":"200","author":"SB Montesi","year":"2019","unstructured":"Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: first-in-human studies. Am J Respir Crit Care Med. 2019;200:258\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR19","doi-asserted-by":"publisher","first-page":"eadj1444","DOI":"10.1126\/sciadv.adj1444","volume":"10","author":"HJ Lee","year":"2024","unstructured":"Lee HJ, Bernau K, Harr TJ, Rosenkrans ZT, Kessler GA, Stott K, Oler AT, Rahar B, Zhu T, Medina-Guevara Y, et al. [(64)Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis. Sci Adv. 2024;10:eadj1444.","journal-title":"Sci Adv"},{"key":"3107_CR20","doi-asserted-by":"publisher","first-page":"14181","DOI":"10.1073\/pnas.1817442116","volume":"116","author":"N Jailkhani","year":"2019","unstructured":"Jailkhani N, Ingram JR, Rashidian M, Rickelt S, Tian C, Mak H, Jiang Z, Ploegh HL, Hynes RO. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A. 2019;116:14181\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3107_CR21","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1091\/mbc.E19-03-0140","volume":"30","author":"JT Saunders","year":"2019","unstructured":"Saunders JT, Schwarzbauer JE. Fibronectin matrix as a scaffold for procollagen proteinase binding and collagen processing. Mol Biol Cell. 2019;30:2218\u201326.","journal-title":"Mol Biol Cell"},{"key":"3107_CR22","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1091\/mbc.e02-01-0048","volume":"13","author":"J Sottile","year":"2002","unstructured":"Sottile J, Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell. 2002;13:3546\u201359.","journal-title":"Mol Biol Cell"},{"key":"3107_CR23","doi-asserted-by":"crossref","unstructured":"Herrera J, Forster C, Pengo T, Montero A, Swift J, Schwartz MA, Henke CA, Bitterman PB. Registration of the extracellular matrix components constituting the fibroblastic focus in idiopathic pulmonary fibrosis. JCI Insight 2019, 4.","DOI":"10.1172\/jci.insight.125185"},{"key":"3107_CR24","doi-asserted-by":"crossref","unstructured":"Herrera JA, Dingle L, Montero MA, Venkateswaran RV, Blaikley JF, Lawless C, Schwartz MA. The UIP\/IPF fibroblastic focus is a collagen biosynthesis factory embedded in a distinct extracellular matrix. JCI Insight 2022, 7.","DOI":"10.1172\/jci.insight.156115"},{"key":"3107_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev-cellbio-100109-104020","volume":"26","author":"P Singh","year":"2010","unstructured":"Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397\u2013419.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"3107_CR26","doi-asserted-by":"publisher","first-page":"23430","DOI":"10.1074\/jbc.M103467200","volume":"276","author":"BR Tomasini-Johansson","year":"2001","unstructured":"Tomasini-Johansson BR, Kaufman NR, Ensenberger MG, Ozeri V, Hanski E, Mosher DF. A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly. J Biol Chem. 2001;276:23430\u20139.","journal-title":"J Biol Chem"},{"key":"3107_CR27","doi-asserted-by":"publisher","first-page":"41087","DOI":"10.1074\/jbc.M110.153692","volume":"285","author":"LM Maurer","year":"2010","unstructured":"Maurer LM, Tomasini-Johansson BR, Ma W, Annis DS, Eickstaedt NL, Ensenberger MG, Satyshur KA, Mosher DF. Extended binding site on fibronectin for the functional upstream domain of protein F1 of Streptococcus pyogenes. J Biol Chem. 2010;285:41087\u201399.","journal-title":"J Biol Chem"},{"key":"3107_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11095-018-2412-7","volume":"35","author":"P Zbyszynski","year":"2018","unstructured":"Zbyszynski P, Tomasini-Johansson BR, Peters DM, Kwon GS. Characterization of the PEGylated Functional Upstream Domain peptide (PEG-FUD): a potent fibronectin assembly inhibitor with potential as an anti-fibrotic therapeutic. Pharm Res. 2018;35:126.","journal-title":"Pharm Res"},{"key":"3107_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40580-019-0192-3","volume":"6","author":"P Zbyszynski","year":"2019","unstructured":"Zbyszynski P, Toraason I, Repp L, Kwon GS. Probing the subcutaneous absorption of a PEGylated FUD peptide nanomedicine via in vivo fluorescence imaging. Nano Converg. 2019;6:22.","journal-title":"Nano Converg"},{"key":"3107_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jconrel.2022.08.028","volume":"350","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Gari MK, Inman DR, Rosenkrans ZT, Burkel BM, Olson AP, Engle JW, Hernandez R, Ponik SM, Kwon GS. Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer. J Control Release. 2022;350:284\u201397.","journal-title":"J Control Release"},{"key":"3107_CR31","unstructured":"Gupta N, Bernau K, Lee HJ, Oler AT, Rahar B, Harr TJ, Stott K, Zhu T, Sandbo NS. Kwon: Fibronectin (FN) binding efficacy of PEGylated FUD (PEG-FUD) peptide in bleomycin treated animal model for the treatment of pulmonary fibrosis. American Assoc Pharma Scie. 2023."},{"key":"3107_CR32","doi-asserted-by":"crossref","unstructured":"Bernau K, Gupta TJHN, Stott K, Rahar B, Oler AT, Medina-Guevara Y, Lee HJ, Gari MK, Burkel BM, Tomasini B, Ponik SM, Engle J, Hernandez R, Kwon G, Sandbo NK. PEG-FUD, A Promising Probe for Pulmonary Fibrosis, Targets the Pro-fibrotic Phase of Disease. American Thoracic Society Conference 2024, B29 Biomarkers and new therapeutics targets in lung Fibrosis.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3225"},{"key":"3107_CR33","unstructured":"Stott K, Oler HJLAT, Rahar B, Harr TJ, Medina-Guevara Y, Gupta N, Holbert K, Rosenkrans Z, Kwon GS, Engle JW, Hernandez R, Sandbo N, Bernau K. Fibrotic precision-cut lung slices for assessment of radiolabeled probe targeting. Pulmonary Fibros Foundation Summit 2023."},{"key":"3107_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.exer.2017.08.017","volume":"165","author":"MS Filla","year":"2017","unstructured":"Filla MS, Dimeo KD, Tong T, Peters DM. Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells. Exp Eye Res. 2017;165:7\u201319.","journal-title":"Exp Eye Res"},{"key":"3107_CR35","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1074\/jbc.M111.294041","volume":"287","author":"LM Maurer","year":"2012","unstructured":"Maurer LM, Ma W, Eickstaedt NL, Johnson IA, Tomasini-Johansson BR, Annis DS, Mosher DF. Ligation of the fibrin-binding domain by beta-strand addition is sufficient for expansion of soluble fibronectin. J Biol Chem. 2012;287:13303\u201312.","journal-title":"J Biol Chem"},{"key":"3107_CR36","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00259-016-3442-1","volume":"43","author":"H Sun","year":"2016","unstructured":"Sun H, England CG, Hernandez R, Graves SA, Majewski RL, Kamkaew A, Jiang D, Barnhart TE, Yang Y, Cai W. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:2169\u201379.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3107_CR37","doi-asserted-by":"publisher","first-page":"12806","DOI":"10.1073\/pnas.1509667112","volume":"112","author":"H Luo","year":"2015","unstructured":"Luo H, Hernandez R, Hong H, Graves SA, Yang Y, England CG, Theuer CP, Nickles RJ, Cai W. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci U S A. 2015;112:12806\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3107_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.apradiso.2007.05.012","volume":"65","author":"MA Avila-Rodriguez","year":"2007","unstructured":"Avila-Rodriguez MA, Nye JA, Nickles RJ. Simultaneous production of high specific activity 64Cu and 61Co with 11.4\u00a0MeV protons on enriched 64Ni nuclei. Appl Radiat Isot. 2007;65:1115\u201320.","journal-title":"Appl Radiat Isot"},{"key":"3107_CR39","doi-asserted-by":"crossref","unstructured":"Bernau K, Ngam C, Torr EE, Acton B, Kach J, Dulin NO, Sandbo N. Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis. Respir Res 2015, 16.","DOI":"10.1186\/s12931-015-0206-6"},{"key":"3107_CR40","doi-asserted-by":"crossref","unstructured":"Bernau K, Leet JP, Bruhn EM, Tubbs AJ, Zhu T, Sandbo N. Expression of serum response factor in the lung mesenchyme is essential for development of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2021.","DOI":"10.1152\/ajplung.00323.2020"},{"key":"3107_CR41","doi-asserted-by":"crossref","unstructured":"Bernau K, Skibba M, Leet JP, Furey S, Gehl C, Li Y, Zhou J, Sandbo N, Brasier AR. Selective inhibition of bromodomain-containing protein 4 reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis. Front Mol Med 2022, 2.","DOI":"10.3389\/fmmed.2022.842558"},{"key":"3107_CR42","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1160\/TH09-03-0141","volume":"102","author":"B Tomasini-Johansson","year":"2009","unstructured":"Tomasini-Johansson B, Mosher DF. Plasma fibronectin concentration in inbred mouse strains. Thromb Haemost. 2009;102:1278\u201380.","journal-title":"Thromb Haemost"},{"key":"3107_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2144\/000112729","volume":"44","author":"RH Hubner","year":"2008","unstructured":"Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, Freitag-Wolf S, Bewig B. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44:507\u201311. 514\u2009\u2013\u2009507.","journal-title":"Biotechniques"},{"key":"3107_CR44","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","volume":"11","author":"M Strunz","year":"2020","unstructured":"Strunz M, Simon LM, Ansari M, Kathiriya JJ, Angelidis I, Mayr CH, Tsidiridis G, Lange M, Mattner LF, Yee M, et al. Alveolar regeneration through a Krt8\u2009+\u2009transitional stem cell state that persists in human lung fibrosis. Nat Commun. 2020;11:3559.","journal-title":"Nat Commun"},{"key":"3107_CR45","doi-asserted-by":"publisher","first-page":"819","DOI":"10.15252\/msb.20156123","volume":"11","author":"HB Schiller","year":"2015","unstructured":"Schiller HB, Fernandez IE, Burgstaller G, Schaab C, Scheltema RA, Schwarzmayr T, Strom TM, Eickelberg O, Mann M. Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol. 2015;11:819.","journal-title":"Mol Syst Biol"},{"key":"3107_CR46","doi-asserted-by":"publisher","first-page":"F1293","DOI":"10.1152\/ajprenal.00117.2019","volume":"316","author":"SLK Bowers","year":"2019","unstructured":"Bowers SLK, Davis-Rodriguez S, Thomas ZM, Rudomanova V, Bacon WC, Beiersdorfer A, Ma Q, Devarajan P, Blaxall BC. Inhibition of fibronectin polymerization alleviates kidney injury due to ischemia-reperfusion. Am J Physiol Ren Physiol. 2019;316:F1293\u20138.","journal-title":"Am J Physiol Ren Physiol"},{"key":"3107_CR47","doi-asserted-by":"crossref","unstructured":"Tomasini-Johansson BRZP, Toraason I, Peters DM, Kwon GS. PEGylated pUR4\/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease. PLoS One 2018, In press.","DOI":"10.1371\/journal.pone.0205360"},{"key":"3107_CR48","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/ATVBAHA.108.181081","volume":"29","author":"HY Chiang","year":"2009","unstructured":"Chiang HY, Korshunov VA, Serour A, Shi F, Sottile J. Fibronectin is an important regulator of flow-induced vascular remodeling. Arterioscler Thromb Vasc Biol. 2009;29:1074\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3107_CR49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jhep.2014.06.010","volume":"62","author":"E Altrock","year":"2015","unstructured":"Altrock E, Sens C, Wuerfel C, Vasel M, Kawelke N, Dooley S, Sottile J, Nakchbandi IA. Inhibition of fibronectin deposition improves experimental liver fibrosis. J Hepatol. 2015;62:625\u201333.","journal-title":"J Hepatol"},{"key":"3107_CR50","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.118.034609","volume":"138","author":"I Valiente-Alandi","year":"2018","unstructured":"Valiente-Alandi I, Potter SJ, Salvador AM, Schafer AE, Schips T, Carrillo-Salinas F, Gibson AM, Nieman ML, Perkins C, Sargent MA, et al. Inhibiting fibronectin attenuates fibrosis and improves cardiac function in a model of heart failure. Circulation. 2018;138:1236\u201352.","journal-title":"Circulation"},{"key":"3107_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2613.2002.00220.x","volume":"83","author":"G Izbicki","year":"2002","unstructured":"Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83:111\u20139.","journal-title":"Int J Exp Pathol"},{"key":"3107_CR52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","volume":"56","author":"RG Jenkins","year":"2017","unstructured":"Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Konigshoff M, Kolb M, Laurent GJ, Nanthakumar CB, Olman MA, Pardo A, et al. An official American thoracic Society Workshop Report: Use of Animal models for the Preclinical Assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol. 2017;56:667\u201379.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3107_CR53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1183\/09031936.93.05040404","volume":"5","author":"J Hernnas","year":"1992","unstructured":"Hernnas J, Nettelbladt O, Bjermer L, Sarnstrand B, Malmstrom A, Hallgren R. Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in the rat. Eur Respir J. 1992;5:404\u201310.","journal-title":"Eur Respir J"},{"key":"3107_CR54","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1016\/S0021-9258(18)32672-3","volume":"258","author":"JW Tamkun","year":"1983","unstructured":"Tamkun JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem. 1983;258:4641\u20137.","journal-title":"J Biol Chem"},{"key":"3107_CR55","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.mbplus.2020.100046","volume":"8","author":"CM Fonta","year":"2020","unstructured":"Fonta CM, Arnoldini S, Jaramillo D, Moscaroli A, Oxenius A, Behe M, Vogel V. Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes. Matrix Biol Plus. 2020;8:100046.","journal-title":"Matrix Biol Plus"},{"key":"3107_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/0016-5085(88)90550-1","volume":"94","author":"LR Schiller","year":"1988","unstructured":"Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology. 1988;94:933\u201341.","journal-title":"Gastroenterology"},{"key":"3107_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.mvr.2015.01.010","volume":"98","author":"WH Reinhart","year":"2015","unstructured":"Reinhart WH, Piety NZ, Goede JS, Shevkoplyas SS. Effect of osmolality on erythrocyte rheology and perfusion of an artificial microvascular network. Microvasc Res. 2015;98:102\u20137.","journal-title":"Microvasc Res"},{"key":"3107_CR58","doi-asserted-by":"publisher","first-page":"e10600","DOI":"10.1002\/btm2.10600","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioeng Transl Med. 2024;9:e10600.","journal-title":"Bioeng Transl Med"},{"key":"3107_CR59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.progpolymsci.2012.07.006","volume":"38","author":"WJ Li","year":"2013","unstructured":"Li WJ, Zhan P, De Clercq E, Lou HX, Liu XY. Current drug research on PEGylation with small molecular agents. Prog Polym Sci. 2013;38:421\u201344.","journal-title":"Prog Polym Sci"},{"key":"3107_CR60","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1164\/rccm.200802-228OC","volume":"179","author":"JE Choi","year":"2009","unstructured":"Choi JE, Lee SS, Sunde DA, Huizar I, Haugk KL, Thannickal VJ, Vittal R, Plymate SR, Schnapp LM. Insulin-like growth factor-I receptor blockade improves outcome in mouse model of lung injury. Am J Respir Crit Care Med. 2009;179:212\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3107_CR61","first-page":"2550","volume":"119","author":"CJ Scotton","year":"2009","unstructured":"Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest. 2009;119:2550\u201363.","journal-title":"J Clin Invest"},{"key":"3107_CR62","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/annrheumdis-2018-214322","volume":"78","author":"J Schniering","year":"2019","unstructured":"Schniering J, Benesova M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick CA, Schibli R, Distler O, et al. Visualisation of interstitial lung disease by molecular imaging of integrin alphavbeta3 and somatostatin receptor 2. Ann Rheum Dis. 2019;78:218\u201327.","journal-title":"Ann Rheum Dis"},{"key":"3107_CR63","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00259-019-04586-z","volume":"47","author":"PT Lukey","year":"2020","unstructured":"Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, Garman N, Costa M, Kendrick S, Onega M, et al. Clinical quantification of the integrin alphavbeta6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL study). Eur J Nucl Med Mol Imaging. 2020;47:967\u201379.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3107_CR64","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1165\/rcmb.2013-0039OC","volume":"49","author":"P Caravan","year":"2013","unstructured":"Caravan P, Yang Y, Zachariah R, Schmitt A, Mino-Kenudson M, Chen HH, Sosnovik DE, Dai G, Fuchs BC, Lanuti M. Molecular magnetic resonance imaging of pulmonary fibrosis in mice. Am J Respir Cell Mol Biol. 2013;49:1120\u20136.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3107_CR65","doi-asserted-by":"crossref","unstructured":"Deng X, Liu J, Zhou J, Shi Y, Song S, Chen J, Li Y, Yu B, Liang SH, Zhu X. Imaging Pulmonary fibrosis and treatment efficacy in vivo with autotaxin-specific PET ligand [(18)F]ATX-1905. Mol Pharm 2024.","DOI":"10.1021\/acs.molpharmaceut.4c00571"},{"key":"3107_CR66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2967\/jnumed.122.264530","volume":"64","author":"D Izquierdo-Garcia","year":"2023","unstructured":"Izquierdo-Garcia D, Desogere P, Fur ML, Shuvaev S, Zhou IY, Ramsay I, Lanuti M, Catalano OA, Catana C, Caravan P, Montesi SB. Biodistribution, Dosimetry, and pharmacokinetics of (68)Ga-CBP8: A type I collagen-targeted PET probe. J Nucl Med. 2023;64:775\u201381.","journal-title":"J Nucl Med"},{"key":"3107_CR67","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s11307-023-01845-2","volume":"25","author":"S Shuvaev","year":"2023","unstructured":"Shuvaev S, Knipe RS, Drummond M, Rotile NJ, Ay I, Weigand-Whittier JP, Ma H, Zhou IY, Roberts JD Jr., Black K, et al. Optimization of an allysine-targeted PET probe for quantifying fibrogenesis in a mouse model of Pulmonary Fibrosis. Mol Imaging Biol. 2023;25:944\u201353.","journal-title":"Mol Imaging Biol"},{"key":"3107_CR68","doi-asserted-by":"crossref","unstructured":"Chen HH, Waghorn PA, Wei L, Tapias LF, Schuhle DT, Rotile NJ, Jones CM, Looby RJ, Zhao G, Elliott JM et al. Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis. JCI Insight 2017, 2.","DOI":"10.1172\/jci.insight.91506"},{"key":"3107_CR69","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0002-9440(10)63464-5","volume":"163","author":"S Li","year":"2003","unstructured":"Li S, Van Den Diepstraten C, D\u2019Souza SJ, Chan BM, Pickering JG. Vascular smooth muscle cells orchestrate the assembly of type I collagen via alpha2beta1 integrin, RhoA, and fibronectin polymerization. Am J Pathol. 2003;163:1045\u201356.","journal-title":"Am J Pathol"},{"key":"3107_CR70","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1074\/jbc.M114.606186","volume":"290","author":"EE Torr","year":"2015","unstructured":"Torr EE, Ngam CR, Bernau K, Tomasini-Johansson B, Acton B, Sandbo N. Myofibroblasts exhibit enhanced Fibronectin Assembly that is intrinsic to their contractile phenotype. J Biol Chem. 2015;290:6951\u201361.","journal-title":"J Biol Chem"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03107-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:26:55Z","timestamp":1737556015000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03107-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3107"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03107-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were approved by the University of Wisconsin-Madison IACUC (protocol numbers M005823 and M005532). No human subjects or tissues were used in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"BRTJ, GSK, NS, and KB are inventors on an issued patent application (pub. no. US10828372B2; date of application granted: 10 November 2020) held by Wisconsin Alumni Research Foundation that covers the PEGylation of FN-binding peptides and their application in fibrosis. RH is a consultant to Archeus Technologies Inc. and MonoPar Therapeutics Inc. He is a member of the science advisory board of Archeus. None of these activities have any relation to imaging of pulmonary fibrosis. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}